Literature DB >> 1540167

Stimulation of 5-fluorouracil metabolic activation by interferon-alpha in human colon carcinoma cells.

E L Schwartz1, M Hoffman, C J O'Connor, S Wadler.   

Abstract

Interferon-alpha (IFN alpha) increases the cytotoxicity of 5-fluorouracil (FUra) in vitro, and the combination has clinical efficacy against advanced colorectal cancer. IFN alpha treatment of HT-29 colon carcinoma cells induced a greater than two-fold increase in the intracellular levels of the active metabolite of FUra, FdUMP. Using cell extracts from HT-29 cells and FUra as substrate, IFN alpha produced a 1.9- and 8.7-fold increase, respectively, in the activities of uridine phosphorylase and pyrimidine nucleoside phosphorylase (PyNP). Furthermore, the effect was selective for the conversion of FUra to FdUMP, as IFN alpha did not increase the cellular levels of FUTP, nor did it change the extent of incorporation of FUra into RNA (or DNA). IFN alpha also had no effect on thymidine kinase activity, the second step in the activation of FUra. Hence the effect of IFN alpha on PyNP activity is likely a critical biochemical event that modulates the cytotoxicity of FUra.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1540167     DOI: 10.1016/0006-291x(92)91863-l

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  23 in total

1.  Differential expression of uridine phosphorylase in tumors contributes to an improved fluoropyrimidine therapeutic activity.

Authors:  Deliang Cao; Amy Ziemba; James McCabe; Ruilan Yan; Laxiang Wan; Bradford Kim; Michael Gach; Stuart Flynn; Giuseppe Pizzorno
Journal:  Mol Cancer Ther       Date:  2011-09-27       Impact factor: 6.261

Review 2.  Structural analyses reveal two distinct families of nucleoside phosphorylases.

Authors:  Matthew J Pugmire; Steven E Ealick
Journal:  Biochem J       Date:  2002-01-01       Impact factor: 3.857

Review 3.  Modulation of 5-fluorouracil by interferon: a review of potential cellular targets.

Authors:  R Horowitz; E L Schwartz; S Wadler
Journal:  Med Oncol       Date:  1995-03       Impact factor: 3.064

4.  Hepatocellular carcinoma, with portal thrombus after viral eradication, disappeared by 5-fluorouracil and interferon.

Authors:  Tomofumi Miura; Nobuaki Suzuki; Junichiro Nakamura; Satoshi Yamada; Tsutomu Miura; Masahiko Yanagi; Hiroyuki Usuda; Iwao Emura; Toru Takahashi
Journal:  World J Hepatol       Date:  2010-11-27

5.  Combination therapy of intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma.

Authors:  Kazuhiro Kasai; Akira Ushio; Yukiho Kasai; Kei Sawara; Yasuhiro Miyamoto; Kanta Oikawa; Hidekatsu Kuroda; Yasuhiro Takikawa; Kazuyuki Suzuki
Journal:  Int J Clin Oncol       Date:  2010-12-04       Impact factor: 3.402

6.  Five-day infusional fluorodeoxyuridine with oral leucovorin and escalating doses of interferon alpha-2b: a phase I study.

Authors:  E E Vokes; S M O'Brien; N J Vogelzang; R L Schilsky; M J Ratain
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

7.  Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5'-deoxy-5-fluorouridine.

Authors:  H Eda; K Fujimoto; S Watanabe; M Ura; A Hino; Y Tanaka; K Wada; H Ishitsuka
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

8.  The modulating effect of interferon alpha-2a on the antitumor activity of UFT against a human gastric carcinoma xenograft, SC-1-NU, in nude mice.

Authors:  T Kubota; N Kurihara; S Kase; M Watanabe; K Kumai; M Kitajima; T Inada
Journal:  Surg Today       Date:  1996       Impact factor: 2.549

9.  Successful treatment of multiple hepatocellular carcinoma with tumor thrombi in the major portal branches by intraarterial 5-fluorouracil perfusion chemotherapy combined with subcutaneous interferon-alpha and hepatectomy.

Authors:  Tameyoshi Yamamoto; Hiroaki Nagano; Yasuharu Imai; Kazuto Fukuda; Hitoshi Matsumoto; Motoi Kondo; Hideo Ota; Masato Nakamura; Hiroshi Wada; Takehiro Noda; Bazarragchaa Damdinsuren; Keizo Dono; Koji Umeshita; Shoji Nakamori; Masato Sakon; Kenichi Wakasa; Morito Monden
Journal:  Int J Clin Oncol       Date:  2007-04-27       Impact factor: 3.402

10.  Combination of interferon-alpha and 5-fluorouracil inhibits endothelial cell growth directly and by regulation of angiogenic factors released by tumor cells.

Authors:  Hiroshi Wada; Hiroaki Nagano; Hirofumi Yamamoto; Takehiro Noda; Masahiro Murakami; Shogo Kobayashi; Shigeru Marubashi; Hidetoshi Eguchi; Yutaka Takeda; Masahiro Tanemura; Koji Umeshita; Yuichiro Doki; Masaki Mori
Journal:  BMC Cancer       Date:  2009-10-12       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.